MACBON Pharm Ltd SC774143 false 2023-06-29 2024-04-30 2024-04-30 The principal activity of the company is Dispensing chemist Digita Accounts Production Advanced 6.30.9574.0 true true SC774143 2023-06-29 2024-04-30 SC774143 2024-04-30 SC774143 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2024-04-30 SC774143 core:CurrentFinancialInstruments core:WithinOneYear 2024-04-30 SC774143 core:Non-currentFinancialInstruments 2024-04-30 SC774143 core:Non-currentFinancialInstruments core:AfterOneYear 2024-04-30 SC774143 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-04-30 SC774143 bus:SmallEntities 2023-06-29 2024-04-30 SC774143 bus:AuditExemptWithAccountantsReport 2023-06-29 2024-04-30 SC774143 bus:FilletedAccounts 2023-06-29 2024-04-30 SC774143 bus:SmallCompaniesRegimeForAccounts 2023-06-29 2024-04-30 SC774143 bus:RegisteredOffice 2023-06-29 2024-04-30 SC774143 bus:Director1 2023-06-29 2024-04-30 SC774143 bus:Director2 2023-06-29 2024-04-30 SC774143 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2023-06-29 2024-04-30 SC774143 bus:PrivateLimitedCompanyLtd 2023-06-29 2024-04-30 SC774143 core:OtherRelatedParties 2023-06-29 2024-04-30 SC774143 countries:Scotland 2023-06-29 2024-04-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: SC774143

MACBON Pharm Ltd

Unaudited Filleted Abridged Financial Statements

for the Period from 29 June 2023 to 30 April 2024

 

MACBON Pharm Ltd

Contents

Company Information

1

Abridged Balance Sheet

2 to 3

Notes to the Unaudited Abridged Financial Statements

4 to 6

 

MACBON Pharm Ltd

Company Information

Directors

Mr Ronald Adrian Badger

Mrs Lynne Barbara Badger

Registered office

3 Bank Avenue
Milngavie
Glasgow
Lanarkshire
G62 8NG

Accountants

Hamilton Morris Waugh
Chartered Certified Accountants
34 Dufferin Avenue
Bangor
Down
BT20 3AA

 

MACBON Pharm Ltd

(Registration number: SC774143)
Abridged Balance Sheet as at 30 April 2024

Note

2024
£

Fixed assets

 

Investment property

33,781

Investments

4

1,877,522

 

1,911,303

Current assets

 

Cash at bank and in hand

 

267

Creditors: Amounts falling due within one year

(635,119)

Net current liabilities

 

(634,852)

Total assets less current liabilities

 

1,276,451

Creditors: Amounts falling due after more than one year

(1,321,176)

Accruals and deferred income

 

(570)

Net liabilities

 

(45,295)

Capital and reserves

 

Called up share capital

6

2

Retained earnings

(45,297)

Shareholders' deficit

 

(45,295)

For the financial period ending 30 April 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

 

MACBON Pharm Ltd

(Registration number: SC774143)
Abridged Balance Sheet as at 30 April 2024

Approved and authorised by the Board on 29 January 2025 and signed on its behalf by:
 

.........................................
Mr Ronald Adrian Badger
Director

 

MACBON Pharm Ltd

Notes to the Unaudited Abridged Financial Statements for the Period from 29 June 2023 to 30 April 2024

1

General information

The company is a private company limited by share capital, incorporated in Scotland.

The address of its registered office is:
3 Bank Avenue
Milngavie
Glasgow
Lanarkshire
G62 8NG
Scotland

These financial statements were authorised for issue by the Board on 29 January 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Investment property

Investment property is carried at fair value, derived from the current market prices for comparable real estate determined annually by external valuers. The valuers use observable market prices, adjusted if necessary for any difference in the nature, location or condition of the specific asset. Changes in fair value are recognised in profit or loss.

 

MACBON Pharm Ltd

Notes to the Unaudited Abridged Financial Statements for the Period from 29 June 2023 to 30 April 2024

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

MACBON Pharm Ltd

Notes to the Unaudited Abridged Financial Statements for the Period from 29 June 2023 to 30 April 2024

3

Staff numbers

The average number of persons employed by the company (including directors) during the period, was 0.

4

Investments

Total
£

Cost or valuation

Additions

1,877,522

Provision

Carrying amount

At 30 April 2024

1,877,522

2024
£

5

Debtors

Debtors includes £Nil due after more than one year.

6

Share capital

Allotted, called up and fully paid shares

2024

No.

£

Share Capital of £1 each

2

2

   

7

Related party transactions

Summary of transactions with other related parties

Ronald Badger

Director & Shareholder

 
At the year end, the amount owed to the director was £329,522.